Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;20(1):74-81.
doi: 10.4048/jbc.2017.20.1.74. Epub 2017 Mar 24.

Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study

Jai Min Ryu  1 , Hyun-June Paik  1 , Sungmin Park  1 , Ha Woo Yi  1 , Seok Jin Nam  1 , Seok Won Kim  1 , Se Kyung Lee  1 , Jonghan Yu  1 , Soo Youn Bae  1 , Jeong Eon Lee  1
Affiliations

Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study

Jai Min Ryu et al. J Breast Cancer. 2017 Mar.

Abstract

Purpose: The use of immediate breast reconstruction (IBR) following total mastectomy (TM) has increased markedly in patients with breast cancer. As the indications for IBR have been broadened and more breast-conserving surgery-eligible patients are undergoing IBR, comparing the oncologic safety between TM only and IBR following TM becomes more difficult. This study aimed to analyze the oncologic outcomes between TM only and IBR following TM via a matched case-control methodology.

Methods: A retrospective review was conducted to identify all patients who underwent TM between 2008 and 2014. We excluded patients who underwent neoadjuvant chemotherapy, including palliative chemotherapy, and had a follow-up duration <12 months, inflammatory breast cancer, or incomplete data. We divided the remaining patients into two groups: those who underwent TM only (control group) and those who underwent IBR following TM (study group). The groups were propensity score-matched. Matched variables included age, pathologic stage, estrogen or progesterone receptor status, human epidermal growth factor receptor 2 status, and year of operation.

Results: After matching, 878 patients were enrolled in the control group and 580 patients in the study group. The median follow-up duration was 43.4 months (range, 11-100 months) for the control group and 41.3 months (range, 12-100 months) for the study group (p=1.000). The mean age was 47.3±8.46 years for the control group and 43.9±7.14 years for the study group (p>0.050). Matching was considered successful for the matching variables and other factors, such as family history, histology, multiplicity, and lymphovascular invasion. There were no significant differences in overall survival (log-rank p=0.454), disease-free survival (log-rank p=0.186), local recurrence-free survival (log-rank p=0.114), or distant metastasis-free survival rates (logrank p=0.537) between the two groups.

Conclusion: Our results suggest that IBR following TM is a feasible treatment option for patients with breast cancer.

Keywords: Breast neoplasms; Mammaplasty; Treatment outcome.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1. Schematic diagram of patient's selection for the matched study.
TM=total mastectomy; NAC=neoadjuvant chemotherapy; F/U= follow-up; IBR=immediate breast reconstruction; NSM=nipple-sparing mastectomy; NNSM=non-NSM; ER=estrogen receptor; PR= progesterone receptor; HER2=human epidermal growth factor receptor 2.
Figure 2
Figure 2. Kaplan-Meier survival curves according to operation type for overall survival (A), disease-free survival (B), distant metastasis-free survival (C), and locoregional recurrence-free survival (D).
TM=total mastectomy; IBR=immediate breast reconstruction.
Figure 3
Figure 3. Kaplan-Meier survival curves between nipple-sparing mastectomy (NSM) and non-NSM (NNSM) among the study group for overall survival (A), disease-free survival (B), distant metastasis-free survival (C), and locoregional recurrence-free survival (D).
See this image and copyright information in PMC

References

    1. Min SY, Kim Z, Hur MH, Yoon CS, Park EH, Jung KW, et al. The basic facts of Korean breast cancer in 2013: results of a nationwide survey and breast cancer registry database. J Breast Cancer. 2016;19:1–7. - PMC - PubMed
    1. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9–16. - PubMed
    1. Albornoz CR, Bach PB, Mehrara BJ, Disa JJ, Pusic AL, McCarthy CM, et al. A paradigm shift in U.S. breast reconstruction: increasing implant rates. Plast Reconstr Surg. 2013;131:15–23. - PubMed
    1. Toth BA, Lappert P. Modified skin incisions for mastectomy: the need for plastic surgical input in preoperative planning. Plast Reconstr Surg. 1991;87:1048–1053. - PubMed
    1. Duraes EF, Durand P, Duraes LC, Orra S, Moreira-Gonzalez A, Sousa JB, et al. Comparison of preoperative quality of life in breast reconstruction, breast aesthetic and non-breast plastic surgery patients: a cross-sectional study. J Plast Reconstr Aesthet Surg. 2016;69:1478–1485. - PubMed